|
Patent landscape, scope, and claims summary: |
United States Patent 9,585,955 (US9585955): Claim Scope and Critical Patent Landscape Analysis for Nitrous Oxide + Fatty-Acid Adjuvanted Vaccines
Executive summary: US 9,585,955 claims a vaccine-administration method and pharmaceutical preparations in which (i) the vaccine antigen is “not inactivated by nitrous oxide,” (ii) an adjuvant is a nitrous oxide gas solution in a pharmaceutically acceptable carrier solvent (including water, alcohols, ethers, oils, polymers such as polyethylene glycol), and (iii) the adjuvant includes at least one specified fatty acid or derivative (including C1–C6 alkyl esters, glycerol-PEG esters, and reaction products such as hydrogenated castor-oil/ricinoleic-acid oils reacted with ethylene oxide, plus ricinoleic-acid-based oil derivatives and “Vitamin F Ethyl Ester”). Dependent claims narrow to antigen classes, target diseases/agents, specific carrier/product variants, and administration routes (oral, nasal/bronchial/pulmonary spray, injectable, topical/buccal/vaginal creams/ointments/suppositories, and transdermal patch reservoir). The novelty sits in the nitrous-oxide solvated adjuvant and the defined fatty-acid derivative system, coupled with the “antigen not inactivated by nitrous oxide” limitation that drives both enforceability and design-around paths.
What is US Patent 9,585,955 claiming: nitrous oxide adjuvants with fatty acids and vaccine antigen “not inactivated”?
Core independent claims:
-
Claim 1 (method): enhance direct or subsequent immunological responses to a vaccine containing an antigen by administering a vaccine+adjuvant composition where:
- the antigen is not inactivated by nitrous oxide;
- the adjuvant is a solution of nitrous oxide gas in a carrier solvent from water or pharmaceutically acceptable alcohol/ether/oil/polymer (incl. polyethylene glycol);
- the adjuvant further comprises at least one fatty acid or derivative selected from the enumerated list (oleic/linoleic/alpha- and gamma-linolenic/arachidonic/eicosapentaenoic/docosahexaenoic/ricinoleic + C1–C6 alkylesters, glycerol-polyethylene glycol esters, and reaction products of hydrogenated natural oils comprising ricinoleic-acid-based oils).
-
Claim 2 (preparation): pharmaceutical preparation of vaccine+adjuvant with the same defining features as Claim 1.
Independent-claim structure matters for claim construction:
- The limitation that the antigen is “not inactivated by nitrous oxide” is a functional/operational constraint. In litigation, that typically pushes analysis toward evidence of antigen integrity after contact with nitrous oxide under claimed formulation/handling conditions, not merely a general statement about nitrous oxide being compatible.
- The adjuvant system is tightly structurally defined: nitrous oxide gas dissolved in a specified carrier solvent family plus enumerated fatty acids/derivatives and particular “reaction product” categories.
How do the “adjuvant” and “antigen not inactivated” limitations interact?
The claims require both:
- an adjuvant containing nitrous oxide solution and specified fatty-acid derivative(s), and
- a vaccine antigen that remains active (not inactivated) in the context of that nitrous oxide formulation.
This coupling is a double-edged sword:
- It can support validity (more specific than generic “gas adjuvants”).
- It also creates a potential vulnerability: competitors can attempt to show their antigen is inactivated under their conditions, or to avoid literal coverage by changing formulation conditions so that nitrous oxide is present but antigen is inactivated (or, conversely, that the asserted “not inactivated” condition is not met).
What is the likely inventive focal point?
Based on claim language, the inventive center is:
- solubilized nitrous oxide as an adjuvant, and
- pairing it with specific fatty-acid/ricinoleic-acid derivative systems (including ethylene-oxide-derived reaction products from castor oil/hydrogenated ricinoleic-acid-based oils).
How strong is the patent estate for US9585955: what parts of the claim are narrow vs defensible?
1) Narrow elements that can be design-around targets
These are the most salient “literal escape” levers:
- Nitrous oxide must be in solution in a specified carrier solvent category. Replacing nitrous oxide with another gas, using a non-solubilized form, or using a carrier outside the recited solvent categories can avoid literal claim coverage.
- Fatty acid must match the enumerated list or derivatives defined. A different adjuvant lipid system (even one that is functionally similar) is an immediate avenue for noninfringement arguments.
- Reaction products are not generic “fatty acid derivatives.” They are tied to particular chemistry:
- reaction product of hydrogenated natural oils comprising ricinoleic acid based oils, and
- specifically reaction with ethylene oxide in dependent claims.
2) Defensible elements for enforcement
- The combination of (a) nitrous oxide dissolved in a pharmaceutically acceptable carrier and (b) specific fatty acid/derivatives yields a specific, testable formulation requirement.
- The broad solvent genus (“water, alcohol, ether, oil or polymer including polyethylene glycol”) can capture many practical vehicles, reducing straightforward solvent-based design-around.
3) Litigation leverage created by “not inactivated”
“Not inactivated by nitrous oxide” is both:
- a potential enforcement tool (prosecution history and specification evidence can support that the patent teaches how to preserve antigen integrity), and
- a potential indefiniteness or proof burden point, depending on how the record defines the metric of “inactivation” and the experimental conditions.
In enforcement strategy, this limitation usually drives:
- comparative assays (antigen binding, infectivity for live agents where applicable, protein integrity, potency readouts),
- formulation exposure times/temperatures, and
- analytical chemistry showing antigen preservation.
Which vaccine antigens does US9585955 cover: peptides, inactivated viruses/bacteria, VLPs, and named diseases?
Dependent claim coverage of antigen type (Claims 3, 13)
- Claim 3 narrows Claim 1 where antigen is selected from:
antigenic peptides, inactivated viruses, inactivated bacteria, and virus-like particles (VLPs).
- Claim 13 mirrors this for Claim 2.
This antigen set is important because it is not “all vaccines.” It is anchored to classes that are plausibly compatible with formulation-induced antigen integrity issues.
Dependent claim coverage of target diseases/agents (Claims 4, 14, 12/11 route links)
Claim 4 lists causative agents and ailments including:
- Bacillus Calmette-Guerin (BCG), Cholera, Haemophilus influenzae type B, Meningococcal, Pertussis, Pneumococcal, Tetanus, Typhoid, Diphtheria, Hepatitis A, Hepatitis B, Human papilloma virus, Influenza, Measles, Mumps, Poliomyelitis, Rabies, Rubella, Tick-borne Encephalitis, Varicella, Yellow Fever.
Claim 14 narrows similarly for preparations. These disease lists are broad enough to cover many mainstream vaccine programs, but they are still dependent limitations. Independent claims are not limited to these disease lists as provided.
What does this mean for a freedom-to-operate analysis?
- A product that uses a different antigen type (e.g., live attenuated virus/bacteria, nucleic acid vaccines, recombinant proteins not described as “VLPs” or “inactivated” in the claim language) may avoid dependent claim coverage.
- But it may still fall under independent Claim 1/2 if the antigen is within “vaccine containing an antigen” and is proven “not inactivated by nitrous oxide,” unless the specification or prosecution narrows antigen scope elsewhere.
What formulations are protected by US9585955: nitrous oxide dissolved in water/alcohol/ether/oil/PEG plus fatty acids and ricinoleic derivatives?
Adjuvant solvent/carrier genus (Claim 1/2)
Carrier solvent is selected from:
- water
- one or more pharmaceutically acceptable alcohol
- ether
- oil
- polymer including polyethylene glycol (PEG)
This structure gives wide practical vehicle coverage across aqueous and many lipid/polymer carriers.
Nitrous oxide physical state requirement
The adjuvant comprises:
- solution of nitrous oxide gas in the carrier solvent.
Dependent Claim 6/16 adds:
- aqueous solution saturated with nitrous oxide,
- water deionised and purified free of microbes and endotoxins.
Dependent Claim 7/17 extends to liquid presentations and details that fatty acids/esters are dissolved/suspended/emulsified along with the antigen.
Fatty acid and derivative system (Claim 1/2)
Enumerated fatty acids:
- oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid,
- eicosapentaenoic acid [C20:5w3],
- decosahexaenoic acid [C22:6w3],
- ricinoleic acid.
Enumerated derivatives:
- C1–C6 alkyl esters,
- glycerol-polyethylene glycol esters,
- reaction product of hydrogenated natural oils comprising ricinoleic acid based oils (and in later dependent claims, castor oil with ethylene oxide).
Specific “Vitamin F Ethyl Ester” coverage (Claim 10/21)
Claim 10 and Claim 21 narrow the fatty-acid component to:
- the complex known as Vitamin F Ethyl Ester.
This is an important additional anchor for enforcement if a competitor uses that specific product.
Ricinoleic-based reaction products and ethylene oxide (Claims 5, 15, 19, 20)
- Claims 5/15: reaction product of hydrogenated natural oils comprising ricinoleic acid based oils with ethylene oxide, produced from castor oil where fatty acid content is predominantly ricinoleic acid.
- Claims 19/20: reaction product is castor oil with ethylene oxide.
These are among the most specific claim elements and likely define the strongest nontrivial patent differentiator.
What route-of-administration claim coverage exists: nasal/mucosal, oral, injectable, topical, vaginal, and transdermal patch?
Liquid, spray, injectable presentations (Claims 7, 17)
Claim 7 covers:
- liquid for oral administration,
- nasal or bronchial or pulmonary spray,
- injectable formulation,
with formulation guidance: the solvent is where nitrous oxide is dissolved; fatty acids/esters are dissolved/suspended/emulsified along with the antigen.
Topical/buccal/nasal/vaginal semi-solids and suppositories (Claims 8, 18)
Claim 8 covers creams, ointments, sprays, lotions, suppositories, incorporating:
- solvent containing and preferably saturated with nitrous oxide
- long-chain fatty acid(s) or ester(s)
- optional excipients and carriers.
Transdermal patch reservoir formulation (Claim 9)
Claim 9 adds transdermal application via:
- injectable/ointment/cream/lotion, or
- a skin patch providing reservoir.
Mucosal/nasal emphasis (Claims 11, 22)
Claim 11:
- mucosal administration, in particular nasal.
Claim 22:
- preparation includes mucosal administration adapted, in particular nasal.
This matters for designing around route claims: competitors using non-mucosal routes (e.g., systemic IM/SC only) may reduce dependent claim exposure but still face independent claim coverage unless they avoid the nitrous oxide + fatty-acid formulation constraints.
What are the commercial and licensing implications of US9585955’s scope for vaccine developers?
Who is likely to be in the impact zone
A practical impact zone is companies developing:
- vaccines where adjuvanted formulations are common (most).
- products using oil/lipid or fatty-acid derivatives, especially ricinoleic/castor-oil derived surfactants or reaction products.
- intranasal or mucosal vaccine delivery systems that already rely on lipid-like excipients.
Where the risk is highest
- Products using nitrous oxide dissolved/saturated in aqueous or carrier media and paired with ricinoleic/castor-oil derived ethylene oxide reaction products.
- Products using “Vitamin F Ethyl Ester” as a fatty-acid derivative component.
Where risk is lower
- Products that use different adjuvant chemistry (e.g., saponins like QS-21, MPLA, CpG, polyphosphazene, alum, oil-in-water emulsions without nitrous oxide).
- Products that use nitrous oxide only as a process gas or transient exposure without a stable “solution” formulation and without the specified fatty-acid/derivative system.
- Products that avoid the “antigen not inactivated” condition through formulation redesign and data.
Licensing posture
Given the specificity of the adjuvant component and presence of “not inactivated” functional language, licensing tends to be product-specific:
- a license would likely need to cover formulation composition and antigen-handling conditions.
- a settlement or license agreement would likely include enablement-like commitments on how nitrous oxide is incorporated (saturated solution vs other states) and how antigen integrity is maintained.
What generic entry risks exist for US9585955: how do formulation changes avoid infringement?
Unlike small-molecule generics, vaccine platform changes frequently avoid literal formula patents through:
- different excipients,
- different adjuvant class substitution,
- route shift,
- different antigen format.
For US9585955, the most direct risk mitigation tools are:
- Replace nitrous oxide with a different gas or avoid dissolved/saturated solution characteristics.
- Remove the listed fatty acid/derivative class, especially ricinoleic/castor-ethylene-oxide reaction product variants.
- Use a different fatty-acid derivative not enumerated (outside C1–C6 alkyl esters, glycerol-PEG esters, or hydrogenated ricinoleic-oil reaction products).
- Alter antigen exposure conditions so that the asserted condition “not inactivated by nitrous oxide” is not met under product-specific use, and document antigen potency integrity through product-specific studies.
When does US9585955 lose exclusivity: how to forecast expiration and exclusivity windows
No filing dates, patent term adjustment information, or continuation/divisional data are provided in the prompt. With only the patent number, a precise expiration date cannot be computed reliably here.
How does US9585955 compare with typical vaccine adjuvant patent landscapes?
US9585955 compared to conventional adjuvant families
Most vaccine formulation patents focus on:
- alum/mineral salts,
- oil-in-water emulsions (MF59/AS03-like structures),
- toll-like receptor agonists (CpG, MPLA),
- saponins (QS-21),
- polymeric carriers (PLGA, chitosan),
- cytokine/immune-modulating agents.
US9585955 is distinctive because it:
- uses a gas adjuvant concept delivered as a dissolved/saturated nitrous oxide solution, and
- integrates a specific fatty-acid/ricinoleic derivative system including ethylene-oxide reaction products.
This reduces the overlap with the majority of “traditional” adjuvant estates, but it creates a concentrated claim zone around gas-based nitrous oxide formulation programs.
Overlap with lipid excipient and mucosal delivery patents
Many nasal formulations include:
- fatty acids and esters,
- PEGylated lipids,
- surfactants,
- casting agents for mucosal tolerability.
US9585955’s overlap occurs only when those lipid systems are paired with:
- nitrous oxide dissolved/saturated in the carrier, and
- at least one listed fatty-acid/derivative system, including ricinoleic-based reaction products.
Key Takeaways
- US 9,585,955 is a formulation-and-method patent centered on nitrous oxide dissolved/saturated in a pharmaceutically acceptable carrier, combined with defined fatty acids and derivatives, including ricinoleic/castor-oil ethylene-oxide reaction products.
- The enforceable claim pivot is the coupled limitation that the vaccine antigen is not inactivated by nitrous oxide, which makes formulation-specific experimental evidence central to validity and infringement.
- The strongest risk for competitors is avoidance of design-around by substituting adjuvant excipients that fall outside the enumerated fatty-acid/derivative list or by eliminating nitrous oxide in solution.
- Dependent claims expand protection across antigen types (peptides, inactivated viruses/bacteria, VLPs), named disease targets, and common delivery routes (oral, nasal/mucosal, injectable, topical/vaginal, and transdermal patch reservoirs).
FAQs
-
Does US9585955 cover live attenuated vaccines?
The provided claim text explicitly recites dependent coverage for antigen types including inactivated viruses/bacteria, peptides, and VLPs; live attenuated specifics are not stated in the dependent claim set you provided.
-
Is “Vitamin F Ethyl Ester” the only fatty acid derivative covered?
No. “Vitamin F Ethyl Ester” is one explicit dependent option; independent claims cover enumerated fatty acids and multiple derivative categories, including C1–C6 alkyl esters, glycerol-PEG esters, and hydrogenated ricinoleic-oil reaction products.
-
Can a competitor use a different carrier solvent (e.g., not PEG, not oil, not ether)?
Literal coverage for the adjuvant hinges on the recited solvent genus in Claim 1/2; changing carrier outside that genus is a direct noninfringement path on the solvent element.
-
What route of administration is most tightly covered?
Dependent claims emphasize mucosal and nasal administration (Claims 11/22) and also cover spray, injectable, topical/buccal/vaginal, suppository, and transdermal patch reservoir formats.
-
How does the “antigen not inactivated by nitrous oxide” limitation affect infringement analysis?
It forces product-condition-specific assessment of antigen integrity/potency after formulation and handling involving nitrous oxide, not just the presence of nitrous oxide and the listed excipients.
References (APA)
- United States Patent 9,585,955.
More… ↓
⤷ Start Trial
|
